Clinical Adoption Leverage existing clinical collaborations like the University of Miami Health System study on V.Dox technology to build funded pilot programs in major academic medical centers and wound care clinics, accelerating evidence generation and adoption of bioelectric antimicrobial wound care.

Partnership Channels Expand market reach by pursuing licensing or distribution partnerships with wound care manufacturers and large distributors for Procellera and FlexEFit lines, leveraging established sales channels to access hospitals, surgery centers, and long-term care facilities.

OTC Market Expansion Capitalize on the OTC bioelectric bandage launch to drive clinician and consumer awareness, targeting pharmacies, urgent care clinics, and direct-to-consumer channels while building physician-facing education to support OTC adoption.

PPE Integration Position V.Dox as an infection-control enhancement within PPE by engaging PPE manufacturers and hospital procurement teams to embed microcurrent antimicrobial features in protective equipment and related wound care products.

AMR and Biofilm Focus Differentiate on the technology’s ability to kill broad-spectrum microbes including drug-resistant strains and disrupt biofilms, targeting infection prevention and formulary committees seeking non-silver, non-surfactant wound care solutions.